Local
Sellas (SLS) shares more than double after its leukemia vaccine extended survival in a Phase 3 trial
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: AIStockWire

Key points Sellas' GPS vaccine meets its Phase 3 survival goal What Sellas' REGAL results leave out When Sellas plans to file with the FDA Sellas Life Sciences (SLS) said its experimental leukemia vaccine met the main goal of its Phase 3 trial, with patients in the vaccine group living a median 24.0 months, compared with 14.7 months in the group receiving a doctor's choice of treatment. The vaccine, galinpepimut-S, or GPS, remains investigational and hasn't been approved by the Food and Drug Administration. Sellas hasn't released the trial's secondary results and plans to meet with the FDA to discuss filing for approval, according to its Nov. 17 release. Sellas shares traded at $19.17 at 10:21 a.m. ET on Nov. 17, up 157% from Monday's close of $7.47. They reached $34 before the market opened and traded between $16.72 and $24.89 after the opening bell.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at AIStockWire


